VIDEO: Study assessing cytoreductive nephrectomy in the 'immune checkpoint era'
Click Here to Manage Email Alerts
In this video, Mark W. Ball, MD, discusses the ongoing SWOG S1931 study assessing the use of immune checkpoint inhibitors with or without cytoreductive nephrectomy in patients with renal cell carcinoma.
The study was presented at the 2022 ASCO Genitourinary Cancers Symposium.
“In the last few years, we’ve seen a lot of challenges to the cytoreductive nephrectomy paradigm with the CARMENA study and the SURTIME study, but both of these previous studies have looked at kidney cancer with older agents, with tyrosine kinase inhibitors,” Ball, who is associate program director of the Urologic Oncology Fellowship and assistant research physician in the Urologic Oncology Branch of the National Cancer Institute, told Healio.
He added that the study “will be looking at cytoreductive nephrectomy —now in the immune checkpoint era — so I’m really looking forward to seeing more results in the future from this study,” he said.
Collapse
Healio Interview
Vaishampayan UN, et al. Poster Presentation 6. Presented at: ASCO Genitourinary Cancers Symposium; Feb. 17-19, 2022; San Francisco.
Click Here to Manage Email Alerts